Q-omics provides the consensus-scored CLYBL-AS2 profile across patient tissues and cancer cell-line models. CLYBL-AS2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, CLYBL-AS2 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, CLYBL-AS2 RNA expression shows 6,394 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, HNSC, and STAD as cancer lineages where CLYBL-AS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLYBL-AS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLYBL-AS2 survival associations across molecular data types. CLYBL-AS2 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLYBL-AS2 RNA expression–survival associations across cancer types. High CLYBL-AS2 expression shows unfavorable associations in COAD, UCEC, BRCA, CHOL, LGG and ACC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for CLYBL-AS2 RNA expression.
This table summarizes CLYBL-AS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CLYBL-AS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLYBL-AS2 shows lower tumor expression in KICH and KIRC and higher tumor expression in HNSC, LIHC, BLCA and LUAD. The HNSC box plot shows higher CLYBL-AS2 RNA expression in tumor versus normal tissue (log2 FC = +0.042, t-test p = .008).
This table shows molecular features associated with CLYBL-AS2 in patient tissues and cancer cell lines. In patient samples, CLYBL-AS2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
